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Abstract: Lymphomas are the ﬁ  fth most common cancer in United States with numerous histological subtypes. Integrating 
existing clinical information on lymphoma patients provides a platform for understanding biological variability in presenta-
tion and treatment response and aids development of novel therapies. We developed a cancer Biomedical Informatics Grid™ 
(caBIG™) Silver level compliant lymphoma database, called the Lymphoma Enterprise Architecture Data-system™ 
(LEAD™), which integrates the pathology, pharmacy, laboratory, cancer registry, clinical trials, and clinical data from 
institutional databases. We utilized the Cancer Common Ontological Representation Environment Software Development 
Kit (caCORE SDK) provided by National Cancer Institute’s Center for Bioinformatics to establish the LEAD™ platform 
for data management. The caCORE SDK generated system utilizes an n-tier architecture with open Application Programming 
Interfaces, controlled vocabularies, and registered metadata to achieve semantic integration across multiple cancer databases. 
We demonstrated that the data elements and structures within LEAD™ could be used to manage clinical research data from 
phase 1 clinical trials, cohort studies, and registry data from the Surveillance Epidemiology and End Results database. This 
work provides a clear example of how semantic technologies from caBIG™ can be applied to support a wide range of 
clinical and research tasks, and integrate data from disparate systems into a single architecture. This illustrates the central 
importance of caBIG™ to the management of clinical and biological data.
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Background
Lymphomas are a heterogeneous group of cancers that are characterized by abnormal growth of tissue 
in the lymphatic system. These disorders originate from B-lymphocytes, T-lymphocytes, and natural 
killer (NK) cells. Between 1950 and 1999, the incidence of Non-Hodgkin’s Lymphoma (NHL) increased 
by 90% in the United States,
1 resulting in one of the largest documented increases in cancer. This rapid 
increase may be a result of improved diagnostic techniques and access to medical care, the rise in 
HIV-related NHLs, or other causes. Currently, NHL represents approximately 4% of all cancer diagnoses, 
being the ﬁ  fth most common cancer among men and women.
2 In 2008, 66,120 new cases of NHL and 
8,220 new cases of Hodgkin lymphoma (HL) are expected to be diagnosed in the United States.
2
The World Health Organization (WHO) classiﬁ  cation system divides lymphomas according to the 
cell of origin (B, T/NK) and incorporates morphology, immunophenotype, genetic, and clinical features 
to deﬁ  ne subtypes. Approximately 85% of all NHLs are of  B-cell origin and the remaining 15% of  T-cell 
origin.
3 The WHO classiﬁ  cation schema for NHL was devised to help aid in prognosis and treatment 
decision making. The most frequent clinical entities recognized by the WHO classiﬁ  cation are diffuse 
large B-cell lymphoma (DLBCL, 31%) and follicular lymphoma (FL, 22%). The WHO classiﬁ  cation 
divides HL into 2 main types: classical and lymphocyte-predominant (Table 1). Classical HL accounts 
for 95% of the cases and is further divided into 4 subtypes: nodular sclerosis, mixed cellularity, 
lymphocyte-depleted, and lymphocyte-rich. Current treatment modalities for lymphoma include 
conventional chemotherapy, immunotherapy, radioimmunotherapy, and stem cell transplant. Prognostic 
factors such as age, performance status, and number of relapses can inﬂ  uence how a patient will respond 
to certain treatments.
In order to expedite the development of innovative clinical and therapeutic strategies for lymphoma, 
our oncology informatics group has been developing means to integrate existing clinical information 46
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Table 1. World Health Organization classiﬁ  cation for lymphomas.
Non Hodgkin Lymphomas (NHL)
B-cell Neoplasm, NOS T-cell and NK-cell Neoplasm, NOS
Precursor B-cell Neoplasms Precursor T-cell Neoplasm
– Precursor B lymphoblastic leukemia (9835/3) –   Precursor T lymphoblastic leukemia 
(9837/3)
– Precursor B lymphoblastic lymphoma (9728/3) –   Precursor T lymphoblastic lymphoma 
(9729/3)
– Blastic NK cell lymphoma (9727/3)
Peripheral (mature) B-cell Neoplasms Peripheral (mature) T-cell Neoplasms
– Chronic lymphocytic leukemia (9823/3) – T-cell prolymphocytic leukemia (9834/3)
– Small lymphocytic lymphoma (9670/3) –   T-cell large granular lymphocytic leukemia 
(9831/3)
– B-cell prolymphocytic leukemia (9833/3) – Aggressive NK cell leukemia (9948/3)
– Lymphoplasmacytic lymphoma (9671/3) – Adult T-cell leukemia/lymphoma (9827/3)
– Splenic marginal zone lymphoma (9689/3) –   Extranodal NK/T cell lymphoma, nasal type 
(9719/3)
– Hairy cell leukemia (9940/3) –   Enteropathy type T-cell lymphoma (9717/3)
– Plasmacytoma/Multiple myeloma (9732/3) – Hepatosplenic T-cell lymphoma (9716/3)
– Solitary plasmacytoma of bone (9731/3) –   Subcutaneous panniculitis-like T-cell 
lymphoma (9708/3)
– Extraosseous plasmacytoma (9734/3) – Mycosis fungoides (9700/3)
–   Extranodal marginal zone B-cell lymphoma 
of mucosa-associated lymphoid tissue 
(MALT-lymphoma) (9699/3)
– Sezary Syndrome (9701/3)
– Nodal marginal zone B-cell lymphoma (9699/3) –   Primary cutaneous anaplastic large cell 
lymphoma (9718/3)
– Follicular lymphoma, NOS (9690/3) –   Peripheral T-cell lymphoma, unspeciﬁ  ed 
(9702/3)
– Follicular lymphoma Grade 1 (9690/3) –   Angioimmunoblastic T-cell lymphoma 
(9705/3)
– Follicular lymphoma Grade 2 (9690/3) – Anaplastic large cell lymphoma (9714/3)
– Follicular lymphoma Grade 3 (9690/3) – Lymphomatoid papulosis (9718/1)
– Mantle cell lymphoma (9673/3)
– Diffuse large B-cell lymphoma (9680/3)
– Mediastinal (thymic) large cell lymphoma (9679/3)
– Intravascular large B-cell lymphoma (9680/3)
– Primary effusion lymphoma (9678/3)
– Burkitt lymphoma (9687/3)
– Burkitt lymphoma leukemia (9826/3)
–   B-cell proliferations of uncertain malignant 
potential
– Lymphomatoid granulomatosis (9766/1)
–   Post-transplant lymphoproliferative disorder, 
pleomorphic (9970/1)
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into database systems that support cancer research.
4 
To this end, we designed a platform for integrated 
clinical and biomedical informatics research using 
patient-level data linking the institution’s existing 
clinical trials, cancer registry, clinical, administra-
tive, and pharmacy systems with biological data-
bases. However, semantic integration of data from 
disparate systems remains challenging even when 
similar concepts are represented in different data 
systems.
The Cancer Biomedical 
Informatics Grid
The cancer Biomedical Informatics Grid 
(caBIG™)
5,6 is a voluntary network or grid linking 
individuals and institutions to promote the sharing 
of data and tools. The caBIG™ development and 
research covers clinical trials management sys-
tems, tissue banks, pathology tools, integrated 
cancer research, system architecture, vocabularies, 
common data elements, data sharing, and intel-
lectual capital. The infrastructure and tools estab-
lished by caBIG™ are likely also to have broad 
utility outside the cancer community. Currently, 
more than 900 individuals from over 50 National 
Cancer Institute (NCI)-designated cancer centers 
and a multitude of other organizations are working 
collaboratively on over 70 projects as part of the 
caBIG™ initiative.
5,7
The systems developed within the caBIG™ 
community can be organized into four levels of 
maturity based on different degrees of interoper-
ability defined by the caBIG™ Compatibility 
Guidelines: Legacy, Bronze, Silver, and Gold.
7,8 
Legacy compliance implies no interoperability 
with an external system or resource. In order to 
achieve Bronze compatibility, the resource should 
provide at least programmatic access to data 
through a public, documented application pro-
gramming interfaces (API). Silver compatibility 
requires more conditions, which must provide 
well-documented API that is based upon an object-
oriented abstraction of the underlying data. Gold 
compatibility includes a service–oriented data and 
analytical service grid with standardized service 
advertising and discovery features, and grid–level 
security strategy. Table 2 details the pertinent cat-
egories that must be addressed to obtain caBIG™ 
Silver compliance: 1) programming and messaging 
interfaces; 2) vocabularies, terminologies, and 
ontologies; 3) data elements; and 4) information 
models (shown in Table 2).
7
The caBIG™ is creating a common, extensible 
informatics platform that can integrate diverse data 
types and support interoperable analytic tools in 
areas including clinical trials management, tissue 
banks and pathology, imaging, and integrative 
cancer research. Table 3 displays the various tools, 
infrastructure, and data resources in caBIG™ and 
their roles.
The NCI’s Center for Biomedical Informatics 
and Information Technology (NCIBIIT) has 
developed a set of software packages to support 
application development for cancer research, the 
caCORE Software Development Kit (SDK).
9 This 
SDK provides a platform for data management and 
semantic integration.
The Cancer Common Ontological 
Representation Environment SDK
To establish a common representation within 
this SDK, the cancer Common Ontological 
Table 1. (Continued)
Hodgkin Lymphoma, NOS
–   Nodular lymphocyte predominant Hodgkin lymphoma (9659/3)
– Classical Hodgkin lymphoma (9650/3)
–   Nodular sclerosis classical Hodgkin lymphoma (9663/3)
–   Lymphocyte-rich classical Hodgkin lymphoma (9651/3)
–   Mixed cellularity classical Hodgkin lymphoma (9652/3)
Lymphocyte-depleted classical Hodgkin lymphoma (9653/3)  
Source: Jaffe et al.
3148
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Representation Environment (caCORE) was 
established to provide a framework for developing 
syntactically and semantically interoperable 
biomedical information services. It has several key 
components: the Enterprise Vocabulary Services 
(EVS), the cancer Data Standards Repository 
(caDSR), the Cancer Bioinformatics Infrastructure 
Objects, and the Common Security Module. A brief 
description for these components is included in 
Table 4. Complete documentation and updated 
information on caCORE and its components can 
be found on the NCI Center for Bioinformatics 
(NCICB) web site.
A caCORE SDK generated system has two 
characteristics: 1) a Model Driven Architecture 
that provides a conceptual framework and standards 
for expressing the model, relationships between 
models, and transformations between models using 
the Meta-Object Facility, Unified Modeling 
Language (UML), XML Metadata Interchange 
(XMI), and Common Warehouse Meta-model 
speciﬁ  cations, and 2) an n-tier architecture with 
open API. When a caCORE SDK generated system 
is combined with controlled vocabularies and 
registered metadata, the resulting system is 
semantically integrated with all exposed API 
elements having runtime accessible metadata that 
deﬁ  nes the meaning of the data elements using a 
controlled terminology.
The NCICB has developed the EVS to supply 
controlled vocabularies, and the caDSR to provide 
a dynamic metadata registry
10 specifically for 
cancer informatics applications. Systems developed 
using the caCORE methodology use the same 
approach for deﬁ  ning, registering, and adopting 
data and representation of standards. Clients of 
those systems can therefore extract information 
from multiple data sources using similar API calls, 
and can rely upon the semantic equivalence of the 
data retrieved.
Semantic Structure of caBIG™
One of the problems confronting the biomedical 
data management community is the vast number 
Table 2. Silver level compatibility guidelines.
Sections Compatibility Requirements
Programming and Messaging Interfaces •   Well–described API approved by the caBIG™ 
ARCHWS that provide access to data in the form 
of data objects that are instances of classes 
represented by a domain model.
•   Electronic data formats reviewed and approved by 
the caBIG ARCHWS that are supported for both 
input to and output from the system.
•   Messaging protocols approved by the caBIG™ 
ARCHWS that are supported wherever messaging is 
indicated by the use cases.
Vocabularies/Terminologies and Ontologies •   Terminologies reviewed and validated by the 
caBIG™ VCDEWS that are used for all appropriate 
data collection ﬁ  elds and attributes of data objects.
•   Term deﬁ  nitions must meet VCDEWS workspace 
guidelines.
Data Elements •   CDEs built from controlled terminologies and 
according to practices validated by the VCDEWS 
that are used throughout.
•   CDEs are registered as ISO/IEC 11179 metadata 
components in the caBIG™ Context of the caDSR.
Information Models •   Object-oriented domain information models are 
expressed in UML as class diagrams and as XMI 
ﬁ  les, and are reviewed and validated by VCDEWS.
Abbreviations: API, application programming interfaces; caBIG™, Cancer Biomedical Informatics Grid™;  ARCHWS, Architecture workspace; 
VCDEWS, Vocabulary/Common Data Elements Workspace; CDE, Common Data Elements; ISO, International Organization for Standardi-
zation; IEC, International Electrotechnical Commission; caDSR, cancer Data Standards Repository; UML, Uniﬁ  ed Modeling Language; XMI, 
XML Metadata Interchange.49
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Table 3. caBIG™ tools, infrastructure and data resources.
Category Role
Tools caIntegrator: a novel translational informatics platform that allows 
researchers and bioinformaticians to access and analyze clinical and 
experimental data across multiple clinical trials and studies.
caBIO: a domain model and architecture used to model the rapidly-
changing genomics and proteomics domain and to integrate data from 
numerous sources providing a holistic view of the human and mouse 
genomes.
caTissue Core: a web tissue bank repository tool for biospecimen 
inventory, tracking, and basic annotation
caArray: a web and programmatically accessible array data management 
system
caXchange: a lab integration hub for clinical trials
C3PR: a web patient registration system for clinical trials
Infrastructure caGrid: enables universal mechanisms for providing interoperable 
programmatic access to data and analytics in caBIG™, creates a 
self-described infrastructure wherein the structure and semantics of data 
can be programmatically determined, and provides a powerful means by 
which services available in caBIG™ can be programmatically discovered 
and leveraged
BRIDG: provides a shared view of the dynamic and static semantics that 
collectively deﬁ  ne a shared domain-of-interest
CTODS: provides a single, uniﬁ  ed set of APIs that can access clinical data 
from multiple data sources
caBIO: facilitates the communication and integration of information from 
the various initiatives supported by caBIG™ and NCI
caCORE: helps streamline the informatics development and providing a 
common data management and application development framework
caDSR: stores and manages CDEs developed by caBIG™ participants 
and various NCI-sponsored organizations
EVS: produces the NCI Thesaurus, Metathesaurus and provides NCI with 
licenses for MedDRA, SNOMED, ICD-O-3, and other proprietary 
vocabularies
caCORE SDK: a set of tools that aid in the design and creation of a 
“caCORE-like” software system.
Data Resources caArray: an open-source, web and programmatically accessible array 
data management system
caBIO: a biomedical data system built using a model-driven approach to 
develop objects, data models middleware, vocabularies, and ontologies 
for biomedical research.
Cancer Gene Data Curation Pilot: creates a database of associations 
between genes and diseases and genes and drug compounds derived 
from the biomedical literature.
caIntegrator: provides a mechanism for integrating and aggregating 
biomedical research data and access to a variety of data types
caMOD: provides information about animal models for human cancer to 
the public research community
  Pathway Interaction Database: a highly structured, curated collection of 
information about known biomolecular interactions and key cellular 
processes assembled into signaling pathways
Source: https://cabig.nci.nih.gov/inventory/.50
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of ways that similar or identical concepts are 
described. Such inconsistency in data descriptors 
(metadata) makes it challenging to aggregate and 
manage even modest-sized data sets and share data 
across current information resources. Consider for 
instance, the number of different ways that each 
of the 51 types of lymphoma shown in Table 1 can 
be coded if one or more is represented in various 
administrative, clinical, pathological, radiology, or 
clinical trials databases. Examples of different 
coding schemes include International Classiﬁ  ca-
tion of Diseases, Tenth Revision (ICD-10) 
diagnosis codes,
11 International Classiﬁ  cation of 
Diseases for Oncology (ICD-O) topography and 
histology codes,
12 and institutional representations 
within clinical trials systems that may be based on 
the WHO classification system
13 or the older 
Working Formulation, Kiel, or Revised European-
American Lymphoma classiﬁ  cation systems.
14
In order to address these problems, the NCI 
created the EVS, which forms the semantic 
underpinnings of caCORE. Semantic interoperability 
lies in the UML model, the use of publicly 
accessible terminologies/vocabularies/ontologies 
(EVS-NCI Thesaurus) and the use of publicly 
accessible metadata repository (caDSR). The EVS 
organizes distinct but overlapping terminologies 
and thus provides a rich controlled vocabulary for 
data coding and retrieval including the NCI 
Thesaurus and the NCI Metathesaurus. The con-
trolled terminology component of caBIG™ is 
maintained in the NCI Thesaurus. The NCI 
Metathesaurus is based on National Library Med-
icine’s UML System Metathesaurus supplemented 
with additional cancer-centric vocabulary. It maps 
many biomedical vocabularies useful to the cancer 
community and contains both public domain and 
proprietary vocabularies.
15
The caBIG™ organizes semantic metadata in 
three layers of abstraction, as illustrated in Figure 1. 
At the top level, semantic concepts are organized 
through the NCI Thesaurus, and accessed through 
the EVS. These concepts are related to each other 
through the use of Common Data Elements (CDEs) 
which are stored and accessed through the caDSR. 
The bottom layer is the Domain Model layer where 
each UML class is linked to a concept within the 
NCI Thesaurus, each relationship between UML 
classes is linked to an association, and each 
relationship between a UML class and an attribute 
value is linked to a CDE.
Using the caBIG™ semantic modeling meth-
odology, Tobias et al developed a model by which 
the College of American Pathologists cancer pro-
tocols could be used as the basis for an electronic 
data standard in pathology.
16 Wang et al. developed 
a Lung Cancer Clinical Database Application 
System using caCORE SDK.
17,18 There are approx-
imately 69 Silver compliant systems registered 
with the caBIG™.
19 The models investigate cancer 
registries, clinical trials, gene expression, genom-
ics, and behavioral research data management.
The data system described herein is the ﬁ  rst 
system that aids lymphoma research and is regis-
tered with caBIG™ (http://umlmodelbrowser.nci.
nih.gov/umlmodelbrowser/). As of writing of this 
paper, we are not aware of any other lymphoma 
databases developed using caCORE SDK. How-
ever, there are lymphoma databases developed but 
not registered with caBIG™. For example, the 
Table 4. The key caCORE components.
Component Description
EVS A description-logic based thesaurus and ontology management system. It is a set of 
services and resources that address NCI’s needs for controlled vocabulary.
caDSR A repository that the NCI and its partners use it to create, edit and deploy the Common 
Data Elements.
caBIO A model driven information system using the cancer Common Ontological Representation 
Environment; a synthesis of software, vocabulary, and metadata models for cancer 
research. Each of the caBIO domain objects represents an entity found in biomedical 
research such as Gene, Chromosome, Single Nucleotide Polymorphisms.
CSM A comprehensive and integrated solution to common security objectives. It helps eliminate 
the need for development teams to create their own security methodology.
Abbreviations: EVS, Enterprise Vocabulary System; caDSR, cancer Data Standards Repository; caBIO, cancer Bioinformatics Infrastructure 
Objects; CSM, Common Security Module.51
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Lymphoma NCI Specialized Programs of Research 
Excellence initiated at the University of Iowa/ 
Mayo Clinic is a highly successful lymphoma 
translational research program.
20 The Lymphoma 
Foundation of America is an independent, nonproﬁ  t 
charitable organization that conducts lymphoma 
research especially on dietary factors, environmen-
tal factors, treatment, and genetics.
21 Other national 
lymphoma databases include the Surveillance, 
Epidemiology, and End Result
22 database and 
National Cancer Database.
23
Using the semantic metadata framework 
(Fig. 1), we have developed a caBIG™ silver 
compliant database, the Lymphoma Enterprise 
Architecture Data-system (LEAD™), that estab-
lishes domain speciﬁ  c ontologies and meta–data 
for lymphoma translational research and lym-
phoma clinical research. With LEAD™ deployed, 
we have established reusable data structures for 
institutional case-control studies, national SEER 
cohort studies, and lymphoid malignancy clinical 
trials. This work provides a clear example of how 
semantic technologies from caBIG™ can be 
applied to support a wide range of clinical and 
research tasks, and illustrates the central importance 
of caBIG™ to the management of clinical and 
biological data.
Methods
LEAD™ Development
As a member of caBIG™ community, we followed 
the caCORE SDK guidance and developed LEAD™ 
in accordance with the Silver compatibility guide-
lines. Steps involved in caCORE SDK workﬂ  ow 
and the development of LEAD™ are shown in 
Figure 2.
24 The major steps in the workﬂ  ow include: 
using case development; information modeling; 
semantic annotation; metadata registration; code 
generation; and system deployment.
25 LEAD™ 
development involved creating class diagrams and 
data models within Enterprise Architecture (EA). 
The structure and relationships between classes in 
the LEAD™ model are shown in Figure 3. The 
actual software code, such as API for data access, 
data services, is generated from the model.
In the model, classes represent discrete scientiﬁ  c 
entities. For instance, in LEAD™, a patient’s 
demographic information is denoted by class 
Controlled Terminology Layer (EVS)
Common Data Elements Data (CDE)
Domain Model Layer
id: Long id: String
studyID: String
patientInitial: String
comment: String
fieldIndicator: String
evaluationData: Data
ctcGradeCode: String
actionTakenCode: String
gov.nih.nci.ctom.domain.AdverseEvent edu.emory.wci.lymphoma.AdverseEvent
Common Data Element 2512944 v1.0
Adverse Event Identifier java.lang.Long
Concept C41331
Property Value Domain
Adverse_Event
Identifier java.lang.Long
Object Class
Adverse_Event
Figure 1. Layers of semantic interoperability in caBIG™. Semantic interoperability lies in UML model, use of publicly accessible 
Terminologies/vocabularies/ontologies (EVS–NCI Thesaurus) and use of publicly accessible metadata repository (caDSR).52
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Registration, and his/her histological diagnosis is 
modeled by class Histology. Disparate methods for 
representing diagnosis (e.g. ICD-9 codes, ICD-O 
codes, pathology-free text reports) are semantically 
integrated by mapping to this class. Attributes of 
each class represent speciﬁ  c characteristics of the 
entities and become Data Elements in the software 
system. For example, one of the attributes of 
Histology is deﬁ  ned as ‘immune_phenotype’. In 
addition to classes and attributes, the model also 
speciﬁ  es the associations between classes including 
cardinality and direction. For instance, each patient 
has only one registration record, but he can have 
multiple adverse events. Thus, the association 
between class Onstudy and class AdverseEvent is 
one–to–many relationship. It is important and 
required that the UML model be annotated with 
descriptions. This facilitates the subsequent 
semantic integration. In LEAD™, UML entities 
are matched to vocabulary concepts; and annotated 
by an expert in the subject area (CF).
After the UML model was created, the NCI EVS 
staff were involved the annotation of entities. Once 
the annotated UML model was approved by the 
model owner, it was loaded into the caDSR by the 
NCI EVS staff. The caCORE SDK automatically 
generates code for web services, an API for data 
access and a basic class browser. The class browser 
allows the developer to check the attributes in a 
class, and to search based on the criteria the user 
enters. The result set is displayed for all those 
records that meet the search criteria. Any other 
classes that have associations with this class are 
searched and displayed as well. After the data 
system is deployed biomedical researchers can 
query the system through well-documented API, 
web browsers, or web services.
In this manuscript we describe the use of 
semantic tools to integrate data from heteroge-
neous systems. LEAD™ compiles data from 
multiple data different sources with unique data 
elements including: the ONCORE
®26 data from 
clinical trials, clinical data from Emory Univer-
sity’s legacy administrative (Health Quest: 
hospital; IDX: clinic), cancer registry (IMPAC 
Medical Systems), electronic medical records 
UML Model XMI File
NO
Successful
test?
Approved
Annotated XMI
Compatibility
Review
Semantic
Integration
Workbeach
Code Generator
Public APIs
Metadata Retrieval
caDSR Production
caDSR Stage
caDSR Services
Terminology Services
Verified
EVS Report
EVS
Production
Stage
UML Loader
UML Loader
YES
Figure 2. The caCORE workﬂ  ow. This ﬁ  gure describes the steps involved in creating a silver level compliant system. A UML object model 
is the input into the workﬂ  ow. The model is exported from the format native to the tool it was developed into the standard XMI representation. 
The XMI ﬁ  le is then annotated with terminology services. Once the annotated XMI is reviewed and approved, it is used as input to generate 
code and public APIs, and it is deposited into production caDSR.53
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(Cerner PowerChart), laboratory, pharmacy, 
clinical trials databases
4 and data from populated 
SEER registry. All these data sources have unique 
representations of data elements that are integrated 
using caBIG™ semantic tools (Fig. 3). For 
example, the clinical trials data has information 
on patient identiﬁ  ers, clinical and laboratory data, 
and data on the treatment and response. The 
Emory University clinical data on the other hand 
is comprised of linked data from the clinical, 
administrative, pharmacy and biological databases 
that contains clinical, laboratory, and treatment 
response data coded using different schemas and 
terminology. The SEER data has detailed socio-
demographic information in addition to the details 
on the disease histology, treatments, and survival 
represented in yet another manner. Through 
LEAD™ we integrated the data from these data 
sources into a single comprehensive database with 
a uniﬁ  ed semantic meaning for concepts shared 
across these databases.
The relationship between entities and classes in 
the model and data ﬁ  elds from lymphoma cohort 
studies, SEER registry data, and clinical trials case 
report forms are shown in Figure 4. The EA model 
was used to generate an XMI ﬁ  le and Data Deﬁ  ni-
tion Language Script. Classes and attributes within 
the model were iteratively annotated by authors 
TH, CF, and NCI’s EVS personnel and the ﬁ  nal 
annotated XMI ﬁ  le was uploaded to the caDSR. 
Once the LEAD™ metadata passed compatibility 
review, the ﬁ  nal APIs were created using the SDK 
code generator. Development was implemented on 
and supported by Dell™ PowerEdge™ 1800 web 
server. Once stabilized, the LEAD™ application 
was migrated to a Dell™ PowerEdge™ 6800 
production server running an Oracle 10 g relational 
database.
The Semantic Web is a vision for the next gen-
eration of the Web.
27 The ﬁ  rst generation Web is 
characterized by static and handwritten HTML 
pages; the second generation is characterized by 
Figure 3. Logic Model for lymphoma clinical database developed using Enterprise Architecture. This ﬁ  gure demonstrates the relation-
ships between the key data elements in LEAD™. Components within each key element are not represented in this ﬁ  gure due to practical 
constraints of resolution and size.54
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dynamics and interactive HTML pages. However, 
these two generations share a similar property; the 
information on Web is represented only in natural 
language for human processing. The goal of the 
next generation, namely Semantic Web, is to make 
information on the Web available for computa-
tional processing.
True semantic integration requires a common 
and shared vocabulary. The ontology serves this 
purpose and Semantic Web technology provides 
language for this goal. The World Wide Web 
consortium approved two key Semantic Web 
technologies: the Resource Description Framework 
(RDF) and the Web Ontology Language (OWL). 
The RDF provides a common data model so that 
when RDF is built on top of XML, systems can 
achieve the level of interoperability required by 
highly dynamic and integrated bioinformatics 
applications.
28 Both RDF and OWL are Semantic 
Web standards that provide a framework for shar-
ing the data on the Web. OWL builds on RDF and 
RDF Schema, and adds more vocabulary for 
describing properties and classes. Thus, OWL has 
strict and precise semantics that are not found in 
RDF Schema. As Semantic Web resources become 
mature and available, there is an increasing 
tendency in bioinformatics applications to use 
Semantic Web technologies.
29 This higher level of 
semantic integration may be possible in future 
versions of LEAD™.
To use LEAD™, the researcher interacts with 
a web browser through the Internet to input and 
query the relevant information (Fig. 5). The web 
browser sends the user’s request to the web server, 
the web server parses the requests and transfers the 
requests to the application server, the application 
server accesses the backend database using object-
relational mapping, generates the required content 
dynamically, and sends the response back to the 
web browser through the web server. In order for 
the outside cancer research community to access 
the data stored in the lymphoma clinical database 
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application system, the system provides 
programmatic APIs generated using caCORE SDK 
code generator.
Populating the database 
with lymphoma data
To populate LEAD™, we utilized data sources 
from three ongoing research studies: 1) a cohort 
studies of NHL patients previously treated at 
Emory University, 2) SEER registry data on 
patients with lymphoid malignancies, and 3) phase 1 
lymphoma clinical trials data.
Emory University Clinical Data
Emory University clinical source data for LEAD™ 
was derived from a large linked database that rep-
resents a fully integrated platform combining 
clinical and administrative legacy databases.
4 This 
platform interfaces Emory Healthcare’s existing 
legacy administrative (Health Quest: hospital; 
IDX: clinic), cancer registry (IMPAC Medical 
Systems), electronic medical records (Cerner 
PowerChart), laboratory, pharmacy, clinical trials 
databases creating a stand-alone structured query 
language-(SQL) based data warehouse.
We utilized a series of search strategies to 
identify a joint population of interest containing 
potential patients with selected NHL subtypes; FL, 
DLBCL, and mantle cell lymphoma (MCL). We 
searched the linked database using cancer registry 
ICD-O histology codes to identify patients: FL 
(9690, 9695, 9691, 9698), DLBCL (9680, 9684), 
and MCL (9693).
30 The query also included the 
ICD-O behavior code 3 (malignant neoplasms, 
primary). This query is labeled Q1 in Table 5A. The 
next series of queries involved text searches of the 
electronic medical records using simple free text 
with the histological diagnosis or more complex 
free-text including synonyms from the UML System 
Metathesaurus Concept Search.
4 Each text string 
search was conducted twice, once limited to 
Web Browser
Web Browser
Web Browser
Web Browser
Data from Emory
Clinical System
Outside
Institutions
Grid Services
Firewall Application Server Database Server
Biostatistician
Data Anaylsis and
Report Generation
Lymphoma Data
Repository
Web Server
Figure 5. Architecture for LEAD™. This ﬁ  gure describes the architecture of the Lymphoma Enterprise Architecture Data–system. It contains 
the presentation tier, business tier and data source tier. The web server passes the requests from web browsers and transfers them to the 
application server which then accesses the backend database and generates the required content dynamically and sends the response 
back to the web browser through the web server. Outside community accesses the data through the provided programmatic API.56
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anatomical pathology (AP) reports, and once access-
ing all medical records. Table 5A describes the 
phrases used to identify patients with FL, DLBCL, 
and MCL. A list of 2471 patients was obtained from 
the text search of AP reports and 3170 patients were 
identiﬁ  ed from the text search of electronic medical 
records. Each query deﬁ  nes a different schema for 
representing patients with a lymphoma diagnosis 
within the clinical data repository.
Next, a group of trained abstractors (PS, KB, 
and TH) ascertained each patient’s histological 
diagnosis by reviewing pathology reports and 
medical charts. In all cases, WHO classiﬁ  cation 
schema for NHL was utilized as the gold standard 
for diagnosis.
31 A hematological oncologist (CF) 
resolved all cases where there was uncertainty as 
to whether the WHO criteria were met. The 
pathology-verified diagnosis status for each 
individual was used to calculate the sensitivity and 
speciﬁ  city of each query strategy as follows:
query the data in the relational database. This web 
interface simpliﬁ  es reading and searching SEER 
data. The user interacts with a web interface that 
uses JSP and a set of rich, custom tag libraries to 
provide the view. The Java Server Page commu-
nicates with the database management system 
through object-relational mapping. This provides 
a powerful, ﬂ  exible platform for allowing users to 
query SEER lymphoma data. Moreover, the data 
are stored in a semantic framework such that data 
analyses examining the SEER lymphoma popula-
tions can be readily compared to equivalent 
populations of Emory patients since they are 
mapped to the same LEAD™ concept. The gener-
ated LEAD™ application system is a distributed, 
web-based application which provides two 
interfaces: one is a web-based user interface for 
inputting and querying data; the second provides 
programmatic APIs for outside institutions to query 
the data stored in the backend database using 
object/relational mapping technology (Fig. 5).
Lymphoma clinical trials data
Web forms for the clinical trial database were 
generated using a web application template devel-
oped in J2EE.
32 This web application is meta-data 
driven, which means all the requirements that are 
used to generate a web form are stored in a rela-
tional database (e.g. column names, data types, 
data length, constraints, etc), allowing all of the 
web forms to be generated dynamically. If a change 
needs to be made on the form (e.g. converting a 
text ﬁ  eld to a selection list) no programming effort 
is required. Through modifying the metadata in the 
database by SQL, the change is reﬂ  ected immedi-
ately when the form is reloaded. The web applica-
tion template was used to generate data entry forms 
for database table.
Results
We performed data integration across disparate 
data sources: 1) to illustrate integration capabilities 
of the LEAD™ infrastructure, and 2) to establish 
datasets that facilitate use by physicians and 
researchers with a common interface.
Integration of emory university clinical 
data for cohort studies
Query strategies varied in terms of their sensitivity 
and speciﬁ  city across lymphoma subtypes, but 
 Lymphoma 
Subtype 
Positive
Lymphoma 
Subtype 
Negative
 
Query 
Positive
a b Sensitivity 
= a/a + c
Query 
Negative
c d Speciﬁ  city 
= d/b + d
Individuals identiﬁ  ed by AP and medical reports 
to have a deﬁ  nitive diagnosis of FL, DLBCL, or 
MCLwere integrated into LEAD™ using the 
semantic architecture to map individuals identiﬁ  ed 
by the means described in each query into a uniﬁ  ed 
deﬁ  nition of histological subtype. Data elements 
were mapped into LEAD™ representations using 
a Perl script and loaded into the LEAD™ Oracle 
10 g database.
SEER data
The SEER registry is an authoritative source of 
information on cancer incidence and survival in 
the United States. The SEER limited-use data 
include SEER incidence and population data. 
Eighty-two ﬁ  elds from the SEER dataset have been 
incorporated into LEAD™. Data were obtained in 
a tab-delimited format and mapped to LEAD™ 
data elements.
Next, we built a 2-tier web interface by using 
Java 2 Enterprise Edition (J2EE) technology to 58
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strategies using ICD-O codes had the most 
favorable characteristics (Table 5B). A total of 
930 patients (324 FL, 519 DLBCL, and 87 MCL) 
were veriﬁ  ed by histological diagnosis. Queries 
based on cancer registry histology codes (Q1) had 
high specificity for FL and MCL but not for 
DLBCL. Simple free-text queries of pathology 
reports (Q2) or all medical records documents (Q4) 
had a high sensitivity for FL, DLBCL, and MCL. 
Simple free-text searches of all medical records 
identified 92% of potential FL cases, 64% of 
DLBCL and 89% of potential MCL cases but had 
varying sensitivity and speciﬁ  city: FL (97%, 13%); 
DLBCL (55%, 50%); and MCL (44%, 6%) 
(Table 5B). Queries using additional phrases from 
the UML System synonym list (Q3, Q5) had higher 
speciﬁ  city for FL and DLBCL and higher sensitivity 
for MCL.
No query strategy had ideal characteristics for 
all lymphoma histological subtypes, thus use of a 
combination of strategies, representations, and 
terminologies is required to best identify a robust 
patient population for clinical research. To render 
data gathered using heterogeneous terminologies 
useful, we integrated the resulting data set into 
LEAD™ by mapping heterogeneous representa-
tions for lymphoma histology into the uniﬁ  ed 
meaning ‘Histology Type’ shown in Figure 4. The 
semantically integrated database allows for data 
management and data analysis where histological 
diagnosis has a unique clinical research meaning 
in LEAD™ regardless of how it was coded in the 
source data set.
Integration of surveillance 
epidemiology and end results
22 data
SEER registry data for the years 1973–2005 were 
extracted from the tab-delimited limited-use data 
set. The entire database contains more than 
3.5 million tumors. Lymphoma patients were iden-
tiﬁ  ed from this data set using ICD-O, Third Edition 
codes as described previously.
33 Cases of lym-
phoma were identiﬁ  ed during this time frame and 
classiﬁ  ed into histological diagnosis categories 
using the WHO system shown in Table 1. One or 
more ICD-O codes maps to each histology 
type.
33
Eighty–two ﬁ  elds from the SEER dataset were 
incorporated into LEAD™. Tab-delimited data 
were translated into clinical concepts using the 
SEER Data Dictionary (http://seer.cancer.gov/
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manuals/CD2_popdic.html) and mapped to 
LEAD™ data elements. Figure 4 shows the 
relationships between SEER and LEAD™ data 
elements. The common representation of entities 
and classes between SEER data and other sources 
(Fig. 4) and the relations between entities and 
classes across data sources permit data sharing and 
analysis of data elements with a common meaning. 
The architecture described permits comparative 
analyses of institutional and national datasets that 
address common clinical problems. We have used 
the representation schema and semantic integration 
from LEAD™ to investigate the incidence and 
outcomes for peripheral T-cell lymphoma.
34 In this 
instance, LEAD™ provided a common user inter-
face for researchers to examine data regardless of 
its original source or representation.
Integration of Phase 1 
clinical trials data
FL is the second most frequent lymphoma subtype 
worldwide with a rapidly increasing incidence in 
the Western world. The majority of patients with 
FL present with advanced disease. For these 
patients, there is no standard treatment and the 
clinical course is characterized by a pattern of 
multiple relapses and remissions and a median 
survival of 6.2 years.
33 We have developed an early 
phase clinical trial investigating a novel combina-
tion chemotherapy regimen (bortezomib, rituximab, 
cyclophosphamide, adriamycin, vincristine, and 
prednisone) designed to improve outcomes for 
patients with FL. The primary objectives of this 
study are:
•  To identify the maximal tolerated doses of 
bortezomib and vincristine when used in this 
combination
•  To estimate the complete response rate associ-
ated with this regimen
Table 6 shows the schedule for data collections 
for this lymphoma clinical trial. Figure 6 shows 
an example graphical user interface for entering 
clinical trial data into LEAD™. Data collected 
during the course of the trial are mapped to 
LEAD™ classes and entities as shown in Figure 4. 
Again, since LEAD™ relies on the caBIG™ 
architecture for semantic integration, patients with 
a histological diagnosis of FL within the clinical 
trial can be matched to patients who share the 
same histology in SEER or the Emory lymphoma 
cohort study. Moreover, since the latter dataset 
contains patients who overlap with those treated 
on the clinical trial, data elements that are com-
mon to the two studies may be stored once with 
a common representation and those unique to each 
study are stored as well with the relationships 
between the data elements made explicit as shown 
in Figure 4.
Semantic queries using LEAD™
Viewing caBIG™ semantic metadata as formal 
standard ontology, querying can be deﬁ  ned as the 
search of the members of classes from multiple 
data sources.
35 The most important types of queries 
can be categorized as those that employ joins and 
merges. If the data services are built upon seman-
tically rich metadata, individual members of dif-
ferent classes ought to be related to each other. 
Consider for example an individual member of 
class emory: OnStudy, and an individual of class 
emory: AdverseEvent, whenever a patient is reg-
istered in the clinical trial, this patient has a mem-
ber of class emory: OnStudy. A query such as the 
one that seeks to retrieve information about adverse 
events and event details for a patient, then returns 
the join on the object property OnStudy has Adver-
seEvent in class emory: OnStudy and the object 
property AdverseEvent has AdverseEvent Detail 
in class emory: AdverseEvent. The strength of 
caBIG™ semantics in facilitating data integration 
is obvious, as the join conditions are directly 
speciﬁ  ed by the class properties from the data 
sources.
The LEAD™ model has been registered in 
caDSR and can be searched by NCI UML model 
browser (http://umlmodelbrowser.nci.nih.gov/
umlmodelbrowser/). This model can be deployed 
by another institution to collect and store its lym-
phoma clinical data. Data stored in this manner 
will facilitate data integration and could thus 
promote the conduct of inter-institutional clinical 
trials and epidemiology studies. Moreover, the 
model browser permits queries of the model 
structure and CDEs. An example is querying the 
adverse events CDEs contained in LEAD™. The 
execution of this query would return every 
individual member of AdverseEvent based on the 
same conditions from these two data sources. It 
is worth noting that it is necessary to determine 
one or more data type properties of AdverseEvent, 
i.e. CDEs which have the class AdverseEvent 
as its subject that is shared by both subclasses. 60
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The researcher who adopts the current LEAD™ 
UML model can add more attributes or modify the 
existing attributes in the classes. Readers who are 
interested in query formulation techniques on 
semantic data can further reference papers by 
Shironoshita et al. and Baer et al.
35,36
Investigational review board approval 
and controlling access
We obtained Investigational Review Board (IRB) 
approval for storing and maintaining patient-related 
data for cancer patients, and an IRB approved 
process has been developed for incorporating new 
patient data into our lymphoma database system. 
This database will use the same procedures for 
access control that is used for other Emory conﬁ  -
dential databases. The research database is pro-
tected by the standard Emory Firewall. Dr. Flowers 
reviews any application for passwords and userIDs 
from researchers. The Informatics Project Manager 
(TH) assists investigators in applying for the 
appropriate level of access, in accordance with 
the researcher’s individual protocol.
Discussion
In cancer research, we need to link clinical out-
comes and tissue based research data to support 
the discovery of correlations between molecular 
studies and prognostic and treatment response 
proﬁ  les. Some of the challenges we face in cancer 
research include, but not limited to, data sharing, 
data complexity, and organizational complexity. 
We also need to use shared languages, such as 
XML, RDF, or XOL
37 for reporting. Clinical trials 
are run over many sites, and data is held by mul-
tiple stakeholders and researchers. Thus we need 
to adopt semantic web technologies, including 
RDF and OWL to share and integrate data models, 
which enable us to report results and phenomena 
with shared languages. Moreover, we should and 
make it possible to interpret models with more 
complete and semantically integrated data. 
Figure 6. Graphical user interface for entering adverse event data into LEAD™. This ﬁ  gure is a sample screen shot of the graphical 
user interface for entering clinical trial data into LEAD™.62
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The emergence of grid technologies facilitates the 
collaboration of different centers and allows 
clinical trials to be scattered in different sites. 
However, to be meaningful grid technologies must 
integrate data from multiple stakeholders semanti-
cally. Successful semantic integration involves use 
of controlled vocabularies and structured, standard-
based metadata to unambiguously describe diverse 
data sets.
Signiﬁ  cance
This paper successfully demonstrates the applica-
tion of caCORE SDK in lymphoma research and 
this methodology serves as a model for adoption 
into other cancer research domains, such as lung 
cancer,
32 prostate cancer, and breast cancer. The 
tool sets from the NCI facilitate rapid data model-
ing, data sharing and exchange, and comprehensive 
question answering. Hence the tools can expedite 
drug discovery, cancer detection, and improve 
disease diagnosis and treatment.
Limitations and future work
While there has been substantial progress within 
caBIG™, and in particular in the implementation 
of caGrid, there is still much work in progress. 
Although the caCORE SDK provides a rich set of 
tools to rapidly develop the silver-level compatible 
system, there is no robust search tool that allows 
biomedical researchers easily to search the under-
lying data. Programming effort is still required to 
extract data from the databases. DBsurfer
38 is one 
of such tools that may allow complex queries of 
semantically integrated databases, but open source 
tools are needed in this area.
Another issue addressed by the LEAD™ system 
is the integration of data across numerous legacy 
systems: Health Quest, IDX, IMPAC Medical 
cancer registry, Cerner PowerChart electronic 
medical records, OnCore clinical trials data, and 
other databases. Other valuable data are contained 
in different systems, such as data in spreadsheets 
on personal computers, patient data in electronic 
systems such as The Emory Electronic Medical 
Record, and various other cancer database systems 
that are outside caGrid framework. In the future, 
caCORE SDK must provide tools for integrating 
data from legacy systems coded in various formats 
and performing data quality assurance evaluations. 
Our future work will concentrate on the provision 
of grid-enabled access to our lymphoma cancer 
data and web services within caGrid, through the 
public APIs, XML, SOAP to allow other data hold-
ers to exchange data without intimate knowledge 
of each other’s system implementations.
Conclusion
Lymphomas are a heterogeneous group of cancers 
that require the development of focused research 
and clinical approaches for speciﬁ  c histological 
subtypes. Integrating existing clinical, genomic 
and proteomic information provides a platform for 
examining biological variability in the pathogen-
esis of lymphomas and their responses to treatment 
response and will promote the development of 
innovative treatment strategies. To expedite the 
development of novel therapeutics for lymphoma, 
our oncology informatics group developed a 
caBIG™ silver-level compliant information 
system that incorporates clinical and biological 
data into a semantically integrated structure, 
LEAD™, that supports information sharing 
between cancer research scientists and clinicians. 
The LEAD™ system links cancer registry, pathol-
ogy, clinical, administrative, pharmacy, and 
clinical trials data with biological data elements 
at the patient–level. We demonstrated that the same 
data elements and structures in LEAD™ could be 
used for institutional cohort studies linking data 
across numerous legacy systems,
4 early phase 
lymphoma clinical trials data collection, and 
national SEER registry data on lymphoid malig-
nancies. This caCORE SDK generated system 
built upon an n–tier architecture with open APIs, 
utilizes controlled vocabularies and registered 
metadata to achieve semantic integration. For 
LEAD™ and other caBIG™ compliant systems 
the NCI’s EVS supplies the controlled vocabular-
ies, and the caDSR provides dynamic metadata 
registry. Data from LEAD™ can be combined and 
reused by systems, programmers, and investigators 
in the broader cancer community. We have dem-
onstrated that reusable data structures can be 
applied to a number of research settings and pro-
vided examples from institutional retrospective 
epidemiological studies, national cancer registry 
data queries, and clinical trials. LEAD™ was 
populated with data from three ongoing research 
studies 1) cohort studies of NHL patients previ-
ously treated at Emory University, 2) SEER reg-
istry data for lymphoma, and 3) case report forms 
data from phase 1 clinical trials. Source data for 
each of these research scenarios originated in a 63
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variety of formats and, once stored within 
LEAD™, can be shared and reused based on the 
standards of the caBIG™ architecture. We have 
shown how semantic technologies from caBIG™ 
were applied to support a wide range of clinical 
and research tasks, and our work serves to illustrate 
the central importance of caBIG™ to the manage-
ment of clinical and biological data in cancer 
research. The infrastructure and tools created by 
caBIG™ can also beneﬁ  t researchers outside the 
cancer community.
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